Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Monday, February 19, 2018
 
Recommended for you
Managing Product Recalls: What to Do After a Recall
The National Law Review • Schiff Hardin Llp
Why I Recently Bought Johnson & Johnson
Seeking Alpha • Big Ticket Fund Managers
Geron: The Good, The Bad And The Ugly
Seeking Alpha • Out
FDA OKs Johnson & Johnson's apalutamide for prostate cancer
Seeking Alpha • Douglas W. House
5 things to know about Stryker CEO Kevin Lobo
Becker's Spine Review • Mackenzie Garrity
Global neurosurgical products market to grow at 10.5% CAGR through 2023: 5 observations
Becker's Spine Review • Megan Wood
Johnson & Johnson (JNJ) Reports On Prostate Cancer - Slideshow
Seeking Alpha
Johnson & Johnson: Waiting For A Better Yield
Seeking Alpha • Discount Fountain
Johnson & Johnson Or Pfizer For Dividends?
Seeking Alpha • Doug Carey
Cramer's lightning round: Take a long-term view on Johnson & Johnson
CNBC • Elizabeth Gurdus
 
Recommended for You
Brand Management, Johnson & Johnson
Managing Product Recalls: What to Do After a Recall
The National Law ReviewSchiff Hardin Llp
If a company facing a recall has managed it effectively, the hardest part is probably over. After writing about how companies can prepare for and manage an effective recall, here are strategies companies can use to restore order and maintain brand loyalty...
Share
Actelion Pharmaceuticals, Finance
Why I Recently Bought Johnson & Johnson
Seeking AlphaBig Ticket Fund Managers
Summary Recently initiated a position in JNJ at $129. Take advantage of the recent dip in a blue chip dividend aristocrat. Recent earnings have renewed my trust in the company's long term growth plan backed by a strong pipeline that will fuel...
Share
Health Finance, Johnson & Johnson
Geron: The Good, The Bad And The Ugly
Seeking AlphaOut
Summary The good: Geron has an exciting positive narrative. The bad: Geron has a disturbing negative narrative. The ugly manifests itself in Geron's crazy stock price action as its day of reckoning fast approaches. Geron (GERN) has been a yo-yo stock for...
Share
Cancer, Johnson & Johnson
FDA OKs Johnson & Johnson's apalutamide for prostate cancer
Seeking AlphaDouglas W. House
Under Priority Review status, the FDA approves Johnson & Johnson (JNJ -0.4%) unit Janssen Pharmaceuticals' ERLEADA (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer. Apalutamide is a next-generation oral androgen receptor inhibitor that blocks the action of testosterone in prostate cancer...
Share
Corporate Governance, Health Care Industry
5 things to know about Stryker CEO Kevin Lobo
Becker's Spine ReviewMackenzie Garrity
1. Mr. Lobo was appointed to Stryker's board of directors in July 2014. He is the only member of the board part of Stryker's management. 2. Additionally, Mr. Lobo serves as a board member for Parker Hannifin Corporation, Advanced Medical Technology Association,...
Share
Johnson & Johnson, Stryker Corp
Global neurosurgical products market to grow at 10.5% CAGR through 2023: 5 observations
Becker's Spine ReviewMegan Wood
The global neurosurgical products market is anticipated to grow at a 10.5 percent compound annual growth rate through 2023, according to Wise Guy Reports. Here are five observations: 1. The neurostimulation devices segment is leading the market, due to the increasing supportive...
Share
Cancer, Health Finance
Johnson & Johnson (JNJ) Reports On Prostate Cancer - Slideshow
Seeking Alpha
The following slide deck was published by Johnson & Johnson in conjunction with this event.
Share
Economic Policy, Finance
Johnson & Johnson: Waiting For A Better Yield
Seeking AlphaDiscount Fountain
Summary Johnson & Johnson's dividend yield has gradually been getting less competitive relative to its peers. While the company is still strong, competition in the pharmaceutical sector as well as litigation settlements are potential risk factors. My yield target to invest further...
Share
Finance, Health Finance
Johnson & Johnson Or Pfizer For Dividends?
Seeking AlphaDoug Carey
Summary Solid dividend payers can form the backbone of a retirement portfolio. Good dividend yields are harder to find these days. We must also take into account dividend growth over time. As the market continues to roar higher, the search for strong...
Share
Johnson & Johnson, Twitter Inc
Cramer's lightning round: Take a long-term view on Johnson & Johnson
CNBCElizabeth Gurdus
Johnson & Johnson: "JNJ's been nonstop down. It's actually down for the year. It's down 10 straight points. You know what I say? Buy, buy, buy, because this is one of the highest quality companies in the world. Take a longer term...
Share